Repatha — Total revenues
Amgen Repatha — Total revenues increased by 10.3% to $876.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.5%, from $656.00M to $876.00M. Over 3 years (FY 2021 to FY 2024), Repatha — Total revenues shows an upward trend with a 25.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase reflects successful market penetration and sustained therapeutic adoption, whereas a decrease may signal patent cliffs, generic competition, or loss of market share.
Detailed definition
This metric captures the total net revenue attributed to the specific therapeutic product line after all adjustments for...
Peer comparison
Comparable to net product sales reported by peer biotech companies for their key commercialized assets.
amgn_segment_repatha_evolocumab_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $286.00M | $272.00M | $273.00M | $329.00M | $325.00M | $309.00M | $333.00M | $388.00M | $424.00M | $406.00M | $417.00M | $517.00M | $532.00M | $567.00M | $606.00M | $656.00M | $696.00M | $794.00M | $876.00M |
| QoQ Change | — | -4.9% | +0.4% | +20.5% | -1.2% | -4.9% | +7.8% | +16.5% | +9.3% | -4.2% | +2.7% | +24.0% | +2.9% | +6.6% | +6.9% | +8.3% | +6.1% | +14.1% | +10.3% |
| YoY Change | — | — | — | — | +13.6% | +13.6% | +22.0% | +17.9% | +30.5% | +31.4% | +25.2% | +33.2% | +25.5% | +39.7% | +45.3% | +26.9% | +30.8% | +40.0% | +33.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's repatha — total revenues?
- Amgen (AMGN) reported repatha — total revenues of $876.00M in Q1 2026.
- How has Amgen's repatha — total revenues changed year-over-year?
- Amgen's repatha — total revenues increased by 33.5% year-over-year, from $656.00M to $876.00M.
- What is the long-term trend for Amgen's repatha — total revenues?
- Over 3 years (2021 to 2024), Amgen's repatha — total revenues has grown at a 25.8% compound annual growth rate (CAGR), from $1.12B to $2.22B.
- What does repatha — total revenues mean?
- The total net revenue generated by the specific therapeutic product after all commercial adjustments.